Ezatiostat

Summary

Ezatiostat (TLK199) is an investigational glutathione‑analog prodrug that inhibits the enzyme glutathione‑S‑transferase P1‑1 (GSTP1‑1). It is being evaluated for the treatment of myelodysplastic syndromes (MDS), a group of bone‑marrow disorders that cause ineffective blood‑cell production. By modulating oxidative‑stress pathways and promoting maturation of hematopoietic progenitors, ezatiostat aims to improve red‑cell, white‑cell and platelet counts and reduce the need for transfusions.

Mechanism of Action

Ezatiostat is a prodrug converted to an active metabolite that binds and inhibits GSTP1‑1, a key enzyme that regulates cellular redox balance. GSTP1‑1 inhibition leads to indirect activation of the c‑Jun N‑terminal kinase (JNK) pathway, enhancing differentiation of hematopoietic progenitor cells and promoting apoptosis of dysplastic or malignant clones. The resulting shift in oxidative‑stress signalling is thought to restore more normal marrow maturation and improve peripheral blood counts.

What the Research Shows

Early‑phase clinical studies have explored both oral tablets and a liposomal intravenous formulation of ezatiostat in patients with low‑ to intermediate‑risk MDS. A phase‑1 dose‑escalation trial of oral tablets in 45 patients reported no dose‑limiting toxicities and 17 hematologic‑improvement responses across lineages, including transfusion independence. A parallel phase‑1/2a IV liposomal study in 54 patients demonstrated multilineage responses (24‑50% improvement in erythroid, neutrophil, and platelet counts) and trilineage responses in 25% of those with pancytopenia. Combination therapy with lenalidomide in 19 patients showed erythroid improvement in 25‑40% and transfusion independence in 43% of transfusion‑dependent individuals. A randomized phase‑2 trial of two extended oral dosing schedules in 89 heavily pretreated MDS patients found a 29% erythroid response rate, median response duration of 34 weeks, and a trend toward higher response in patients previously treated with lenalidomide but not hypomethylating agents. Across studies, the most frequent adverse events were mild gastrointestinal symptoms and, for IV dosing, transient infusion‑related reactions.

Reported Benefits

Clinical data indicate that ezatiostat can produce hematologic improvement in erythroid, neutrophil, and platelet lineages, leading to reduced transfusion requirements and, in some cases, transfusion independence. Multilineage and even trilineage responses have been observed, suggesting broader marrow restoration. A small number of patients achieved cytogenetic complete responses, and combination with lenalidomide appeared to enhance efficacy in lenalidomide‑naïve disease. The drug has been generally well tolerated, supporting its potential as a novel therapeutic option for MDS.

Limitations of the Evidence

Evidence to date is limited to early‑phase (phase 1, phase 1/2a, and a single phase 2) trials with modest sample sizes, and no regulatory approval has been granted. Long‑term durability of responses and overall survival benefit remain unproven. Response rates vary by prior therapy and disease subtype, and the optimal dosing schedule has not been definitively established. Larger, controlled studies are needed to confirm efficacy, safety, and comparative advantage over existing treatments.

Safety Considerations

Ezatiostat has been associated mainly with grade 1–2 adverse events. The most common non‑hematologic effects are gastrointestinal (nausea, diarrhea, vomiting) and fatigue or anorexia. Intravenous liposomal administration can cause transient infusion‑related reactions such as chills, flushing, back pain, and dyspnea. No dose‑limiting toxicities were reported in phase‑1 studies, and hematologic toxicities were generally consistent with the underlying disease rather than the drug. Monitoring for GI symptoms and infusion reactions is recommended.

How It Is Administered

Ezatiostat is available as oral tablets (dose‑escalation studies used 200–6000 mg daily on a 21‑day cycle) and as a liposomal intravenous formulation (50–600 mg/m² administered on days 1‑5 of a 14‑ or 21‑day cycle). Both routes have been investigated in clinical trials; the oral form is currently in phase‑2 development, while the IV formulation has been evaluated in phase‑1/2a studies.

Routes of Administration

Goals & Uses

• Improvement of cytopenias (anemia, neutropenia, thrombocytopenia)Hematopoiesis StimulationModerate
• Treatment of myelodysplastic syndromes (MDS)OncologyModerate
• Anticancer/antineoplastic activityOncologyLow
• Reduction of transfusion dependenceSupportive OncologyModerate

Contraindications

• Severe hepatic impairmentOrganModerateLiver function concerns
• Known hypersensitivity to ezatiostat or excipientsAllergyHigh

Adverse Effects

• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• FatigueGeneralCommonLow energy or tiredness
• VomitingGastrointestinalCommonForceful expulsion of stomach contents
• Elevated liver enzymes (transaminases)HepaticUncommon
• Infusion-related reactionsHypersensitivityUncommon
• DiarrheaGastrointestinalCommonLoose or frequent stools

Drug Interactions

• Cytotoxic chemotherapy agentsModerate
• Other glutathione-modulating agentsLow

Population Constraints

• Severe renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Lactating womenReproductiveRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionInvestigationalNot approved by EMA. Investigational status only.
• United StatesInvestigationalReceived FDA Orphan Drug Designation for MDS. Not approved. Phase 2 trials completed; no NDA filed as of last available data.
• United KingdomInvestigationalNot approved by MHRA. Investigational status only.

Ezatiostat received Orphan Drug Designation from the FDA for myelodysplastic syndromes. It has not received full FDA or EMA approval. Development was led by Telik, Inc. Phase 2 trials showed clinical activity but no Phase 3 approval has been granted.

Evidence & Sources

• Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome
  Journal ArticleModerateRaza A, et al.2009-01-01T00:00:00.000000Z
• Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
  Journal ArticleModerateRaza A, et al.2012-01-01T00:00:00.000000Z
• Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome
  Journal ArticleModerateRaza A, et al.2009-01-01T00:00:00.000000Z
• Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes
  Journal ArticleModerateMahadevan D, Sutton GR2015-01-01T00:00:00.000000Z
• Novel therapies for myelodysplastic syndromes
  Journal ArticleModerateSteensma DP2010-01-01T00:00:00.000000Z
• A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome
  Journal ArticleModerateRaza A, et al.2012-01-01T00:00:00.000000Z

Frequently Asked Questions